The randomized controlled period (RCP) in the phase 3 MINT trial of inebilizumab for myasthenia gravis (MG) wasn't reported ...

Switching Medicare Advantage (MA) plans is increasingly common among MA enrollees, especially those dually eligible for ...

Tozorakimab cut moderate/severe COPD exacerbations up to 34% in the phase 3 trials OBERON and TITANIA across smoking status ...

Patients with ≥5 impaired domains experienced markedly worse outcomes versus none, including >2-fold higher mortality and ...

Allocation frameworks do not prohibit age but label 65-70 as higher risk and >70 as high risk, while scoring systems may favor older candidates due to greater waitlist mortality. Pediatric indications ...

1. ZANVASTRO (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) ...

New York’s $76M emphasizes rural care coordination via partnerships and integrated health networks to reduce fragmentation between hospitals, primary care, and community resources. CMS awarded NY, RI, ...

John R. Hurst, MD, PhD, explains how BEAM-302 gene editing targets both lung and liver disease in alpha-1 antitrypsin ...

In addition, Godara noted that toxicity management for bispecific antibodies has evolved. While early use of these therapies ...

A separate poster, drawing on data from the National Institutes of Health's All of Us Research Program, found that women with ...

Concurrent guideline statements have increased classification ambiguity, strengthening arguments for phenotype-first ...

Francesca Puggioni, MD, explains how multidisciplinary teams choose COPD biologics and why systemic inflammation matters as much as FEV1. Multidisciplinary approaches, particularly when treating ...